# Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia

> **NCT02463747** · PHASE4 · UNKNOWN · sponsor: **Tel-Aviv Sourasky Medical Center** · enrollment: 110 (estimated)

## Conditions studied

- Fever
- Febrile Neutropenia

## Interventions

- **DRUG:** Piperacillin/tazobactam
- **DRUG:** Ceftazidim
- **DRUG:** Meropenem
- **DRUG:** Vancomycin

## Key facts

- **NCT ID:** NCT02463747
- **Lead sponsor:** Tel-Aviv Sourasky Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-06
- **Primary completion:** 2017-06
- **Final completion:** 2017-07
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2015-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02463747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02463747, "Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02463747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*